Trial Profile
A phase IIb trial to assess the efficacy and tolerability of IPX 159 in patients with restless legs syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2019
Price :
$35
*
At a glance
- Drugs IPX 159 (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors IMPAX Laboratories
- 21 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Feb 2012 Planned number of patients changed from 120 to 160 as reported by ClinicalTrials.gov.
- 02 Feb 2012 Planned end date (Feb 2013) added as reported by ClinicalTrials.gov.